Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,PA8.DE,19460428.0,67421800,1795176,,-3451519,,-3463856,1984324,385104,-3425200,-3425200,30804,-36924,,,,12337,385104,3810304,0,-26319,,-3463856,-3463856,1829399.0,6859988.0,21289827.0,2055301.0,28149813.0,66241493.0,-185848505.0,140896839.0,13.0,19666309.0,6844559.0,140896839.0,42397.0,26278004.0,4545000.0,1774252.0,3906828.0,-936600.0,318.0,-50660.0,-8460.0,1391965.0,26200.0,-4847372.0,11645.0,-4839875.0,-332480.0,14000.0,-1774252.0,16000.0,275349.0,-13682.0,,19433445.0,en-US,US,EQUITY,False,Delayed Quote,1.86,1630576157,0.0019999743,1.856,1.86,1.848,3078,EUR,GER,125404552,7200000,False,False,REGULAR,4,0.107641235,1.848 - 1.86,de_market,0,PAION O.N,1.858,1.848,1.858,82,200,finmb_2581204,XETRA,Paion AG,EUR,72521,112561,0.18799996,0.11244017,1.672 - 2.819754,-0.9597539,-0.34036794,1.672,2.819754,1617102000,1628577000,1629095400,62.0,0.03,0.321,1.8644571,-0.004457116,-0.0023905705,1.950771,-0.09077096,-0.046530813,5.7943926,15,Europe/Berlin,CEST,1.03,,,2.8198,1.672,1.8645,1.9508,72.52k,112.56k,67.42M,,61.52M,8.32%,5.07%,,,,,,,,,,,0.00%,,"Apr 15, 1998",,,"Dec 31, 2020","Dec 31, 2020",11.31%,8.05%,3.73%,12.34%,19.66M,0.30,-23.00%,19.66M,2.39M,2.22M,0.0300,,19.67M,0.3,26.86k,0.13,3.84,0.32,906.12k,-5.19M,Value,52062,Healthcare,43,"Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",Aachen,49 2414 4530,1609372800,Germany,http://www.paion.com,86400,Martinstrasse 10-12,49 2414 453100,Biotechnology
t-1,PA8.DE,9826259.0,67421800,2094000,,11674000,,11738000,1929000,15750000,11674000,11674000,53000,-36924,,,,-64000,15750000,4076000,0,0,,11738000,11738000,,,11732459.0,,,,,,,,,,,,,,,-466966.0,-12457.0,28254.0,5704.0,277987.0,26200.0,12099777.0,-10283.0,12105813.0,-250786.0,-14000.0,356360.0,-16000.0,451306.0,1543.0,-6550.0,,en-US,US,EQUITY,False,Delayed Quote,1.86,1630576157,0.0019999743,1.856,1.86,1.848,3078,EUR,GER,125404552,7200000,False,False,REGULAR,4,0.107641235,1.848 - 1.86,de_market,0,PAION O.N,1.858,1.848,1.858,82,200,finmb_2581204,XETRA,Paion AG,EUR,72521,112561,0.18799996,0.11244017,1.672 - 2.819754,-0.9597539,-0.34036794,1.672,2.819754,1617102000,1628577000,1629095400,62.0,0.03,0.321,1.8644571,-0.004457116,-0.0023905705,1.950771,-0.09077096,-0.046530813,5.7943926,15,Europe/Berlin,CEST,1.03,,,2.8198,1.672,1.8645,1.9508,72.52k,112.56k,67.42M,,61.52M,8.32%,5.07%,,,,,,,,,,,0.00%,,"Apr 15, 1998",,,"Dec 31, 2020","Dec 31, 2020",11.31%,8.05%,3.73%,12.34%,19.66M,0.30,-23.00%,19.66M,2.39M,2.22M,0.0300,,19.67M,0.3,26.86k,0.13,3.84,0.32,906.12k,-5.19M,Value,52062,Healthcare,43,"Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",Aachen,49 2414 4530,1609372800,Germany,http://www.paion.com,86400,Martinstrasse 10-12,49 2414 453100,Biotechnology
t-2,PA8.DE,9826259.0,67421800,2669570,,-4639656,,-4340546,1745392,19876,-4591653,-4591653,196567,-48003,,,,-299110,19876,4611529,0,-48003,,-4340546,-4340546,1906200.0,9091225.0,11732459.0,3731774.0,20823682.0,65795913.0,-194122560.0,140059106.0,13.0,12413903.0,9071043.0,140059106.0,75729.0,18841740.0,500000.0,356360.0,5310396.0,466966.0,-1543.0,-28254.0,-7704.0,-277987.0,6550.0,-5557777.0,10283.0,-5550813.0,250786.0,-14000.0,-356360.0,14000.0,-1293306.0,-1543.0,-6550.0,9770697.0,en-US,US,EQUITY,False,Delayed Quote,1.86,1630576157,0.0019999743,1.856,1.86,1.848,3078,EUR,GER,125404552,7200000,False,False,REGULAR,4,0.107641235,1.848 - 1.86,de_market,0,PAION O.N,1.858,1.848,1.858,82,200,finmb_2581204,XETRA,Paion AG,EUR,72521,112561,0.18799996,0.11244017,1.672 - 2.819754,-0.9597539,-0.34036794,1.672,2.819754,1617102000,1628577000,1629095400,62.0,0.03,0.321,1.8644571,-0.004457116,-0.0023905705,1.950771,-0.09077096,-0.046530813,5.7943926,15,Europe/Berlin,CEST,1.03,,,2.8198,1.672,1.8645,1.9508,72.52k,112.56k,67.42M,,61.52M,8.32%,5.07%,,,,,,,,,,,0.00%,,"Apr 15, 1998",,,"Dec 31, 2020","Dec 31, 2020",11.31%,8.05%,3.73%,12.34%,19.66M,0.30,-23.00%,19.66M,2.39M,2.22M,0.0300,,19.67M,0.3,26.86k,0.13,3.84,0.32,906.12k,-5.19M,Value,52062,Healthcare,43,"Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",Aachen,49 2414 4530,1609372800,Germany,http://www.paion.com,86400,Martinstrasse 10-12,49 2414 453100,Biotechnology
t-3,PA8.DE,12595196.0,67421800,3730000,,-2152000,,-1711000,1864000,3500000,-2152000,-2152000,58000,-48003,,,,-441000,3500000,5652000,0,0,,-1711000,-1711000,,,14732498.0,,,,,,,,,,,,,,,0.0,-1543.0,-28254.0,-14000.0,-277987.0,6550.0,-815000.0,10283.0,-809000.0,250786.0,-14000.0,-356360.0,-14000.0,902000.0,-1543.0,-6550.0,,en-US,US,EQUITY,False,Delayed Quote,1.86,1630576157,0.0019999743,1.856,1.86,1.848,3078,EUR,GER,125404552,7200000,False,False,REGULAR,4,0.107641235,1.848 - 1.86,de_market,0,PAION O.N,1.858,1.848,1.858,82,200,finmb_2581204,XETRA,Paion AG,EUR,72521,112561,0.18799996,0.11244017,1.672 - 2.819754,-0.9597539,-0.34036794,1.672,2.819754,1617102000,1628577000,1629095400,62.0,0.03,0.321,1.8644571,-0.004457116,-0.0023905705,1.950771,-0.09077096,-0.046530813,5.7943926,15,Europe/Berlin,CEST,1.03,,,2.8198,1.672,1.8645,1.9508,72.52k,112.56k,67.42M,,61.52M,8.32%,5.07%,,,,,,,,,,,0.00%,,"Apr 15, 1998",,,"Dec 31, 2020","Dec 31, 2020",11.31%,8.05%,3.73%,12.34%,19.66M,0.30,-23.00%,19.66M,2.39M,2.22M,0.0300,,19.67M,0.3,26.86k,0.13,3.84,0.32,906.12k,-5.19M,Value,52062,Healthcare,43,"Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",Aachen,49 2414 4530,1609372800,Germany,http://www.paion.com,86400,Martinstrasse 10-12,49 2414 453100,Biotechnology
